Dark

APLS
Apellis Pharmaceuticals, Inc. Common Stock
stock NASDAQ

At Close

May 16, 2025 3:59:30 PM EDT

17.46USD+6.724%(+1.10)5,275,591

0.00Bid 0.00Ask 0.00Spread

Pre-market

May 16, 2025 9:01:30 AM EDT

16.30USD-0.367%(-0.06)10,387

After-hours

May 16, 2025 4:16:30 PM EDT

17.36USD-0.573%(-0.10)18,606

OverviewOptionsHistoricalExchangesShortsNews

Jan 21, 2022

05:21AM EST Apellis Pharma Filing Shows Registration For $300M In Common Stock Benzinga

Jan 11, 2022

04:16PM EST Where Apellis Pharmaceuticals Stands With Analysts Benzinga

07:10AM EST Raymond James Maintains Strong Buy on Apellis Pharmaceuticals, Lowers Price Target to $112 Benzinga

Jan 6, 2022

04:05PM EST Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq GlobeNewswire Inc

Jan 3, 2022

07:00AM EST Apellis Pharmaceuticals,Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on Monday, January 10, 2022 at 8:15 a.m. ET. GlobeNewswire Inc

Dec 15, 2021

10:14AM EST Apellis - Sobi's Pegcetacoplan Wins European Approval For Rare Blood Disorder Benzinga

08:03AM EST The Daily Biotech Pulse: Lilly Raises Guidance, Medtronic Gets FDA Warning Letter, Decision Day For Calliditas, Genenta IPO Benzinga

07:18AM EST Apellis And Sobi Announce EU Approval Of Aspaveli For Treatment Of PNH Benzinga

07:00AM EST Apellis and Sobi Announce EU Approval of Aspaveli GlobeNewswire Inc

Dec 14, 2021

02:51PM EST CRISPR Therapeutics Shares Move Higher; Elon Musk, Responding To Gene Editing Article, Says 'This is the revolution in medicine' Benzinga

Dec 13, 2021

11:46AM EST Apellis And Sobi Say Empaveli Demonstrated Sustained Normalization Of Clinical Measures In Broad PNH Patient Population Benzinga

11:45AM EST Apellis And Sobi Report Empaveli Demonstrated Sustained Normalization Of Clinical Measures In Broad PNH Patient Population Benzinga

11:45AM EST -- Improvements demonstrated in treatment-nave patients and patients with baseline hemoglobin levels greater than or equal to 10.0 g/dL -- Data were presented at the American Society of Hematology (ASH) Annual Meeting GlobeNewswire Inc

Dec 8, 2021

11:26AM EST What 9 Analyst Ratings Have To Say About Apellis Pharmaceuticals Benzinga

10:04AM EST Benzinga's Top Ratings Upgrades, Downgrades For December 8, 2021 Benzinga

07:27AM EST Wells Fargo Initiates Coverage On Apellis Pharmaceuticals with Overweight Rating, Announces Price Target of $84 Benzinga

Nov 30, 2021

04:09PM EST Analyst Ratings For Apellis Pharmaceuticals Benzinga

04:03PM EST Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2021 Benzinga

04:02PM EST Roth Capital Downgrades Apellis Pharmaceuticals to Neutral, Lowers Price Target to $40 Benzinga

Nov 29, 2021

07:00AM EST Apellis Pharmaceuticals,Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will present at the 4th Annual Evercore ISI HealthCONx Conference on Thursday, December 2, 2021 at 8:00 a.m. ET. The conference will be held in a virtual meeting format. GlobeNewswire Inc

Nov 24, 2021

10:11AM EST Citigroup Maintains Buy on Apellis Pharmaceuticals, Raises Price Target to $72 Benzinga

Nov 18, 2021

04:01PM EST Apellis Pharmaceuticals Announces Closing of Public Offering of GlobeNewswire Inc

Nov 16, 2021

08:31AM EST The Daily Biotech Pulse: Kezar Jumps On Data, Biogen R&D Chief To Retire, Molecular Partners Wilts On COVID Trial Disappointment Benzinga

07:26AM EST Apellis Pharmaceuticals Prices 8.75M Share Common Stock Offering At $40/Share Benzinga

07:00AM EST Apellis Pharmaceuticals Announces Pricing of Public Offering of GlobeNewswire Inc

Nov 15, 2021

04:34PM EST Apellis Pharmaceuticals Announces Proposed Public Offering Of $300M Of Common Stock Benzinga

04:01PM EST Apellis Pharmaceuticals Announces Proposed Public Offering of GlobeNewswire Inc

Nov 12, 2021

07:53AM EST Apellis Pharma Plans To Submit NDA For Intravitreal Pegcetacoplan In The First Half Of 2022 RTTNews

07:12AM EST Apellis Pharma Reiterates Plan To Submit New Drug Application In H1'22 For Pegcetacoplan For Geographic Atrophy Following FDA Feedback Benzinga

07:00AM EST Apellis Reiterates Plans to Submit a New Drug Application in the GlobeNewswire Inc

Nov 10, 2021

07:55AM EST Apellis Announces Three Oral Presentations Of The Phase 3 DERBY And OAKS Data In Geographic Atrophy To Be Highlighted At The AAO Annual Meeting Benzinga

07:00AM EST -- Pegcetacoplan, an investigational, targeted C3 therapy, has the potential to become the first treatment for GA, a leading cause of blindness worldwide GlobeNewswire Inc

Nov 9, 2021

01:21PM EST Where Apellis Pharmaceuticals Stands With Analysts Benzinga

11:35AM EST Raymond James Maintains Strong Buy on Apellis Pharmaceuticals, Raises Price Target to $116 Benzinga

11:05AM EST Apellis Pharmaceuticals Q3 EPS $(2.28) Misses $(1.75) Estimate, Sales $5.70M Miss $7.22M Estimate Benzinga

Nov 8, 2021

04:01PM EST -- Generated $5.3 million in EMPAVELI (pegcetacoplan) net product revenues -- Presented Phase 3 DERBY and OAKS results in geographic atrophy (GA); on track for NDA submission in 1H 2022 -- Received positive CHMP opinion for pegcetacoplan for treatment of PNH; expect decision regarding approval by European Commission by end of 2021 -- Conference call scheduled today at 4:30 p.m. ET GlobeNewswire Inc

05:06AM EST Earnings Scheduled For November 8, 2021 Benzinga

Nov 3, 2021

07:00AM EDT Apellis Pharmaceuticals,Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will participate in the following investor conferences in November: GlobeNewswire Inc

Nov 1, 2021

07:00AM EDT Apellis Pharmaceuticals,Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will host a conference call and webcast to discuss its third quarter 2021 financial results on Monday, November 8, 2021 at 4:30 p.m. ET. GlobeNewswire Inc

Oct 15, 2021

07:23AM EDT Apellis And Sobi Receive Positive CHMP Opinion For Aspaveli For Paroxysmal Nocturnal Hemoglobinuria RTTNews

07:19AM EDT Apellis Pharma Reports Positive CHMP Opinion For Aspaveli For Treatment Of Paroxysmal Nocturnal Hemoglobinuria Benzinga

07:17AM EDT Apellis and Sobi Receive Positive CHMP Opinion for GlobeNewswire Inc

Oct 6, 2021

04:05PM EDT Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq GlobeNewswire Inc

Sep 30, 2021

11:57AM EDT Apellis Pharmaceuticals Option Alert: Oct 15 $40 Calls Sweep (3) near the Ask: 500 @ $0.5 vs 4974 OI; Earnings 11/1 Before Open [est] Ref=$33.615 Benzinga

11:52AM EDT Apellis Pharmaceuticals Announces Detailed Results From Phase 3 DERBY And OAKS Studies Presented At Retina Society Annual Meeting Benzinga

11:50AM EDT -- Results further support the efficacy and safety profile of pegcetacoplan, an investigational, targeted C3 therapy, with monthly and every-other-month treatment GlobeNewswire Inc

Sep 20, 2021

07:00AM EDT Apellis Pharmaceuticals,Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will present at the 2021 Cantor Virtual Global Healthcare Conference on Monday, September 27, 2021 at 8:40 a.m. ET. The conference will be held in a virtual meeting format. GlobeNewswire Inc

Sep 10, 2021

07:36PM EDT Mid-Afternoon Market Update: Dow Slides Over 100 Points; Echo Global Logistics Shares Spike Higher Benzinga

07:36PM EDT What 11 Analyst Ratings Have To Say About Apellis Pharmaceuticals Benzinga

07:36PM EDT Why Apellis Pharmaceutical Shares Are Plunging Today Benzinga

07:36PM EDT Mid-Day Market Update: Crude Oil Rises Over 2%; Apellis Pharmaceuticals Shares Plunge Benzinga

07:36PM EDT Why IVERIC Bio Shares Are Soaring Today Benzinga

07:35PM EDT Mid-Morning Market Update: Markets Mixed; Kroger Tops Q2 Views Benzinga

10:19AM EDT Shares of IVERIC bio, Inc. (ISEE) surged over 60% on Friday morning despite no statement from the company to drive the shares. However, IVERIC's stock must have benefited from the news that its rival, Apellis Pharmaceuticals' (APLS) Phase 3 study of eye disease treatment failed to meet its primary endpoint. RTTNews

10:13AM EDT Apellis Pharmaceuticals, Inc. (APLS) shares trading lower on Friday morning trade after its DERBY study of Pegcetacoplan for geographic atrophy or GA failed to meet the primary endpoint, meanwhile, the OAKS study met the primary endpoint for both monthly and every-other-month treatment with pegcetacoplan. RTTNews

10:06AM EDT Benzinga's Top Ratings Upgrades, Downgrades For September 10, 2021 Benzinga

08:57AM EDT Roth Capital Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $46 Benzinga

08:55AM EDT Benzinga Pro's Top 5 Stocks To Watch For Friday, Sept. 10, 2021: FCEL, AFRM, TTOO, APLS, ENDP Benzinga

08:33AM EDT Credit Suisse Maintains Neutral on Apellis Pharmaceuticals, Lowers Price Target to $38 Benzinga

08:29AM EDT 10 Biggest Price Target Changes For Friday Benzinga

08:00AM EDT The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test Benzinga

07:45AM EDT Wedbush Downgrades Apellis Pharmaceuticals to Neutral, Lowers Price Target to $39 Benzinga

07:20AM EDT BMO Capital Maintains Outperform on Apellis Pharmaceuticals, Lowers Price Target to $69 Benzinga

06:19AM EDT Needham Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $70 Benzinga

Sep 9, 2021

04:07PM EDT Apellis Announces Phase 3 DERBY Study In Geographic Atrophy Did Not Meet Primary Endpoint, OAKS Study Met Primary Endpoint Benzinga

04:05PM EDT ApellisAnnounces Top-Line Results from Phase 3 DERBY GlobeNewswire Inc

Sep 7, 2021

04:05PM EDT Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq GlobeNewswire Inc

Aug 19, 2021

12:38PM EDT Where Apellis Pharmaceuticals Stands With Analysts Benzinga

10:10AM EDT Benzinga's Top Ratings Upgrades, Downgrades For August 19, 2021 Benzinga

07:41AM EDT Wedbush Upgrades Apellis Pharmaceuticals to Outperform Benzinga

05:01AM EDT Jefferies Initiates Coverage On Apellis Pharmaceuticals with Buy Rating, Announces Price Target of $74 Benzinga

Aug 10, 2021

08:50AM EDT Credit Suisse Maintains Neutral on Apellis Pharmaceuticals, Raises Price Target to $50 Benzinga

08:03AM EDT Raymond James Maintains Strong Buy on Apellis Pharmaceuticals, Lowers Price Target to $102 Benzinga

Aug 9, 2021

05:28PM EDT Recap: Apellis Pharmaceuticals Q2 Earnings Benzinga

04:10PM EDT Apellis Pharmaceuticals Q2 EPS $(2.72) Down From $(1.57) YoY Benzinga

04:01PM EDT Apellis Pharmaceuticals Reports Second Quarter 2021 Financial Results GlobeNewswire Inc

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

04:11AM EDT Earnings Scheduled For August 9, 2021 Benzinga

Aug 8, 2021

10:11AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Aug 6, 2021

04:05PM EDT Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq GlobeNewswire Inc

Jul 29, 2021

07:00AM EDT Apellis Pharmaceuticals,Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will host a conference call and webcast to discuss its second quarter 2021 financial results on Monday, August 9, 2021 at 4:30 p.m. ET. GlobeNewswire Inc

Jul 26, 2021

07:00AM EDT Apellis Announces Closing of Previously Announced Exchanges of GlobeNewswire Inc

Jul 8, 2021

11:43AM EDT Analyst Ratings For Apellis Pharmaceuticals Benzinga

07:46AM EDT 10 Biggest Price Target Changes For Thursday Benzinga

07:42AM EDT BMO Capital Maintains Outperform on Apellis Pharmaceuticals, Raises Price Target to $89 Benzinga

Jul 7, 2021

10:07PM EDT Apellis Announces Agreements to Exchange Approximately $198.6 GlobeNewswire Inc

04:05PM EDT Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq GlobeNewswire Inc

Jul 2, 2021

10:27AM EDT 10 Biggest Price Target Changes For Friday Benzinga

09:58AM EDT UPDATE: Needham On Apellis Buy Reiteration: Firm Remains Focused On Pegcetacoplan Phase 3 Readout Expected In September 2021 And Believes Treatment Has Potential To Reach 'Blockbuster Status' In Geographic Atrophy Benzinga

09:57AM EDT Needham Reiterates Buy Rating On Apellis Pharmaceuticals With $85 Price Target Benzinga

07:38AM EDT The Daily Biotech Pulse: Iterum's Regulatory Setback, Decision Day For Provention Bio, Cidara & Outset Medical Announce CFO Departures Benzinga

06:31AM EDT JP Morgan Maintains Overweight on Apellis Pharmaceuticals, Raises Price Target to $101 Benzinga

Jul 1, 2021

08:07AM EDT The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts Benzinga

05:48AM EDT Apellis, Beam Ink $75M Deal To Test Base Gene Editing Against Complement Disorders Benzinga

Jun 30, 2021

04:16PM EDT Apellis Pharma Reports Exclusive Research Collab With Beam Therapeutics To Apply Base Editing To Discover Novel Therapies For Complement-Driven Diseases Benzinga

04:15PM EDT Collaboration combines Apellis expertise in complement, a complex biological system, with Beams proprietary base editing platform GlobeNewswire Inc

Jun 28, 2021

12:48PM EDT Apellis Pharmaceuticals Option Alert: Oct 15 $80 Calls at the Ask: 200 @ $13.58 vs 276 OI; Earnings 7/30 Before Open [est] Ref=$64.345 Benzinga

06:05AM EDT Needham Maintains Buy on Apellis Pharmaceuticals, Raises Price Target to $85 Benzinga

Jun 25, 2021

07:32AM EDT The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs Benzinga

Jun 23, 2021

07:00AM EDT Apellis Pharmaceuticals,Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will host a Research and Development Day from 12:30 p.m. to 4:30 p.m. ET on Wednesday, June 30, 2021 in New York City and virtually. GlobeNewswire Inc

Jun 16, 2021

08:20AM EDT The Daily Biotech Pulse: Regeneron COVID-19 Antibody Cocktail Data, FDA Nod For Mallinckrodt, Molecular Partners IPO Benzinga

Jun 15, 2021

08:07AM EDT The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda Benzinga

Jun 11, 2021

08:05AM EDT The Daily Biotech Pulse: Vertex Shelves Mid-Stage Study, Precigen & Novan Jump On Data, Hematology Conference, Janux Debuts Benzinga

Jun 9, 2021

09:14AM EDT The Daily Biotech Pulse: Lyra Gains On Positive Regulatory Outcome, FDA Nod For Pfizer's Prevnar Vaccine, Merck Inks COVID-19 Treatment Supply Deal With US Benzinga

Jun 3, 2021

Jun 2, 2021

10:38AM EDT Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates Benzinga

08:20AM EDT The Daily Biotech Pulse: FDA Nod For Novartis, iRhythm CEO Quits Abruptly, Moderna Inks Vaccine Supply Agreements Benzinga

Jun 1, 2021

05:31PM EDT Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates Benzinga

May 25, 2021

08:21AM EDT Apellis-Sobi Partnered Pegcetacoplan Shows Clinically Meaningful Improvements in Rare Blood Disorder Study Benzinga

07:58AM EDT Swedish Orphan Biovitrum Reports Positive Top-line Results From Phase 3 PRINCE Study Of Pegcetacoplan RTTNews

07:03AM EDT Apellis And Sobi Report Top-line Results From Phase 3 PRINCE Study Of EMPAVELI; Study Demonstrated Statistical Superiority On The Co-Primary Endpoints Benzinga

07:00AM EDT Apellis and Sobi Report Positive Top-line Results from the Phase 3 GlobeNewswire Inc

May 21, 2021

10:27AM EDT Apellis Pharmaceuticals shares were trading higher after UBS initiated coverage on the stock with a Buy rating and announced a price target of $82 per share. Benzinga

10:08AM EDT Benzinga's Top Ratings Upgrades, Downgrades For May 21, 2021 Benzinga

06:36AM EDT UBS Initiates Coverage On Apellis Pharmaceuticals with Buy Rating, Announces Price Target of $82 Benzinga

May 17, 2021

02:32PM EDT Mid-Afternoon Market Update: Nasdaq Drops Over 100 Points; Apellis Pharmaceuticals Shares Spike Higher Benzinga

01:59PM EDT Apellis Pharmaceuticals Shares Up 18%; Roth Raises Price Target From $69 To $80 Benzinga

01:47PM EDT Mid-Day Market Update: Gold Rises 1.5%; FreightCar America Shares Slide Following Q1 Results Benzinga

12:45PM EDT UPDATE: Goldman Sachs Issues Not On Apellis Pharmaceuticals 'Broad Empaveli Approval Sets Stage for Potentially Transformational 2021;Maintain Buy,' Benzinga

12:16PM EDT Mid-Day Market Update: Gold Rises 1.5%; FreightCar America Shares Slide Following Q1 Results Benzinga

10:23AM EDT Mid-Morning Market Update: Markets Down; AT&T, Discovery To Merge Media Assets Benzinga

07:23AM EDT Apellis Stock Is Trading Higher On FDA Approval For Empaveli In Rare Blood Disorder Benzinga

May 14, 2021

06:25PM EDT -- EMPAVELI, the first targeted C3 therapy, is approved for use in adults with PNH who are:Treatment naveSwitching from C5 inhibitor Soliris (eculizumab) Switching from C5 inhibitor Ultomiris (ravulizumab) GlobeNewswire Inc

04:45PM EDT Apellis Pharmaceuticals Gets FDA Approval Of Empaveli For the Treatment Of Paroxysmal Nocturnal Hemoglobinuria Benzinga

07:59AM EDT The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts Benzinga

May 12, 2021

10:06AM EDT -- Seven accepted abstracts, including an oral presentation, reinforce the potential of pegcetacoplan, an investigational, targeted C3 therapy, to redefine treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) GlobeNewswire Inc

May 7, 2021

04:05PM EDT Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq GlobeNewswire Inc

Apr 29, 2021

11:42AM EDT Credit Suisse Maintains Neutral on Apellis Pharmaceuticals, Raises Price Target to $39 Benzinga

Apr 28, 2021

04:15PM EDT Apellis Pharmaceuticals Q1 EPS $(2.32) Misses $(1.62) Estimate Benzinga

04:01PM EDT Apellis Pharmaceuticals Reports First Quarter 2021 Financial Results GlobeNewswire Inc

07:26AM EDT The Daily Biotech Pulse: FDA Rejection For Protalix, Amgen Q1 Trail Estimates, Pfizer Goes Shopping Benzinga

04:15AM EDT Earnings Scheduled For April 28, 2021 Benzinga

Apr 24, 2021

09:24AM EDT The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx Benzinga

Apr 21, 2021

07:00AM EDT Apellis Pharmaceuticals,Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will host a conference call and webcast to discuss its first quarter 2021 financial results on Wednesday, April 28, 2021 at 4:30 p.m. ET. GlobeNewswire Inc

Apr 16, 2021

12:44PM EDT -- 10 accepted abstracts include five oral presentations from pioneering artificial intelligence (AI) collaboration -- Presentations support the potential of intravitreal pegcetacoplan, an investigational targeted C3 therapy, as the first treatment for geographic atrophy (GA) GlobeNewswire Inc

10:08AM EDT Benzinga's Top Ratings Upgrades, Downgrades For April 16, 2021 Benzinga

06:14AM EDT Goldman Sachs Initiates Coverage On Apellis Pharmaceuticals with Buy Rating, Announces Price Target of $130 Benzinga

Apr 13, 2021

07:09AM EDT Apellis Provides 24-Month Update From Phase 1b Study Of Pegcetacoplan In Patients With Geographic Atrophy; Post Hoc Analysis Showed 46% Decrease In Mean Lesion Growth In Eight Patients Benzinga

07:00AM EDT -- Post hoc analysis showed a 46% decrease in mean lesion growth in eight patients with bilateral GA comparing treated eye vs. untreated fellow eye at 24 months (p=0.007) -- Top-line data from Phase 3 DERBY and OAKS studies expected in Q3 2021 GlobeNewswire Inc

Mar 17, 2021

05:53PM EDT Apellis and Sobi Announce The Publication To The New England Journal Of Medicine Of Their Phase 3 PEGASUS Study Results Comparing Pegcetacoplan To Eculizumab For PNH Benzinga

05:48PM EDT -- Pegcetacoplan, an investigational targeted C3 therapy for serious, complement-driven diseases, demonstrated superiority to eculizumab with a statistically significant improvement in hemoglobin levels and showed improvements in key clinical outcomes -- Marketing applications for pegcetacoplan are under Priority Review with the FDA and under review with the EMA GlobeNewswire Inc

Mar 10, 2021

09:15AM EST -- Data published in Ophthalmology and the American Journal of Ophthalmology underscore the potential of pegcetacoplan, an investigational targeted C3 therapy, for geographic atrophy GlobeNewswire Inc

Mar 5, 2021

04:05PM EST Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq GlobeNewswire Inc

06:00AM EST Apellis Pharmaceuticals To Stop Testing APL-9 In Severe COVID-19 Patients Benzinga

Mar 4, 2021

04:13PM EST Apellis Says Will Not Pursue ADditional Development OF APL-9 In Severe COVID-19 After Interim Review By Independent Data Monitoring Committee Found No Meaningful Reduction In The Overall Mortality Rate In Phase 1/2 Study Benzinga

04:05PM EST -- Company will not pursue additional development of APL-9 for the treatment of severe COVID-19 -- Interim review by independent data monitoring committee (DMC) found no meaningful reduction in the overall mortality rate in Phase 1/2 study -- No safety signals were observed by the DMC GlobeNewswire Inc

Feb 26, 2021

08:50AM EST Credit Suisse Maintains Neutral on Apellis Pharmaceuticals, Raises Price Target to $37 Benzinga

Feb 25, 2021

04:25PM EST Apellis Pharmaceuticals Q4 EPS $0.93 Up From $(1.77) YoY, Sales $250.00M May Not Compare To $96.09M Estimate Benzinga

08:08AM EST The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants Benzinga

04:03AM EST Earnings Scheduled For February 25, 2021 Benzinga

Feb 22, 2021

08:00AM EST Apellis Pharmaceuticals,Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will participate in the following investor conferences in March: GlobeNewswire Inc

Feb 18, 2021

04:05PM EST Apellis Pharmaceuticals,Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will host a conference call and webcast to discuss its fourth quarter and full year 2020 financial results on Thursday, February 25, 2021 at 4:30 p.m. ET. GlobeNewswire Inc

Feb 5, 2021

04:05PM EST Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq GlobeNewswire Inc

Jan 29, 2021

10:43AM EST Credit Suisse Maintains Neutral on Apellis Pharmaceuticals, Raises Price Target to $35 Benzinga

Jan 26, 2021

05:00PM EST Apellis Announces Closing of Previously Announced Exchanges of GlobeNewswire Inc

Jan 21, 2021

07:00AM EST Apellis Pharmaceuticals to Host Investor Event on Geographic GlobeNewswire Inc

Jan 8, 2021

10:59AM EST Raymond James Maintains Strong Buy on Apellis Pharmaceuticals, Raises Price Target to $104 Benzinga

07:25AM EST The Daily Biotech Pulse: Sarepta Gene Therapy Study Readout, Novavax Vaccine Supply Deal, 2 IPOs Benzinga

Jan 7, 2021

06:56AM EST Apellis Announces Agreements to Exchange Approximately $107.5 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock Benzinga

06:55AM EST Apellis Announces Agreements to Exchange Approximately $107.5 GlobeNewswire Inc

Jan 5, 2021

07:00AM EST Apellis Pharmaceuticals,Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will present atthe 39th Annual J.P. Morgan Healthcare Conference on Tuesday, January 12, 2021 at 10:50 a.m. ET. The conference will be held in a virtual meeting format. GlobeNewswire Inc

Jan 4, 2021

07:17AM EST Apellis Pharmaceuticals Enters Into A Commercial Supply Agreement With Bachem Americas To Supply Company With The Drug Substance For The Finished Dosage Form Of APL-2 Benzinga

Dec 30, 2020

08:16AM EST The Daily Biotech Pulse: Osmotica Faces Second FDA Rejection, UK Conditionally Approves AstraZeneca's Vaccine Candidate, Hepion NASH Data Benzinga

Dec 29, 2020

08:09AM EST The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica Benzinga

Dec 15, 2020

10:07AM EST Roth Capital Maintains Buy on Apellis Pharmaceuticals, Raises Price Target to $73 Benzinga

07:52AM EST The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding Benzinga

Dec 10, 2020

07:42AM EST The Daily Biotech Pulse: Key Vaccine Adcom Review For Pfizer-BioNTech, Puma, Immutep, G1 Rally On Breast Cancer Conference Presentations Benzinga

06:05AM EST UPDATE: Apellis Pharmaceuticals Says Patients Treated With Pegcetacoplan Maintained Improvements Across Key Secondary Endpoints Benzinga

06:05AM EST Apellis And Sobi Report Top-Lone Results At 48 Weeks From Phase 3 PEGASUS Study Of Pegcetacoplan in PNH Benzinga

06:00AM EST -- Treatment with pegcetacoplan resulted in a sustained improvement in hemoglobin with a mean increasefrom baseline of 2.7g/dLat Week 48, which isequal tothe2.7 g/dL increaseseen at Week 16 with pegcetacoplan-treated patients GlobeNewswire Inc

Dec 7, 2020

10:14AM EST Apellis Reports Pegcetacoplan Demonstrates Greater Treatment Responses, Quality-of-Life Improvements Compared To C5 Inhibitors For PNH Benzinga

10:00AM EST Apellis Reports Pegcetacoplan Demonstrates Greater Treatment GlobeNewswire Inc

Dec 4, 2020

04:05PM EST Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq GlobeNewswire Inc

Nov 30, 2020

07:00AM EST Apellis Pharmaceuticals,Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will present atthe 2020 Evercore ISI HealthCONx Conference on Thursday, December 3, 2020 at 1:25 p.m. ET. The conference will be held in a virtual meeting format. GlobeNewswire Inc

Nov 25, 2020

07:35AM EST The Daily Biotech Pulse: Revance's DAXI Regulatory Decision, Reata Slips On FDA Feedback, Liquidia Setback Benzinga

Nov 24, 2020

08:13AM EST The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia Benzinga

Nov 23, 2020

08:02AM EST 10 Biggest Price Target Changes For Monday Benzinga

07:03AM EST Citigroup Maintains Buy on Apellis Pharmaceuticals, Raises Price Target to $67 Benzinga

Nov 19, 2020

09:41AM EST Benzinga's Top Upgrades, Downgrades For November 19, 2020 Benzinga

06:45AM EST Apellis and Sobi Announce First Patient Dosed in Potentially Registrational ALS Study of Pegcetacoplan Benzinga

06:45AM EST -- 52-week Phase 2 MERIDIAN study to evaluate pegcetacoplan, a targeted C3 therapy, in approximately 200 adults with ALS GlobeNewswire Inc

05:38AM EST Needham Initiates Coverage On Apellis Pharmaceuticals with Buy Rating, Announces Price Target of $59 Benzinga

Nov 16, 2020

07:11AM EST Apellis: FDA Accepts & Grants Priority Review Designation For Pegcetacoplan NDA For Paroxysmal Nocturnal Hemoglobinuria RTTNews

07:03AM EST Apellis Pharma Granted Priority Reivew by the FDA For its New Drug Application for Pegcetacoplan Benzinga

07:00AM EST Apellis Announces FDA Acceptance and Priority Review of the New GlobeNewswire Inc

Nov 13, 2020

10:43AM EST Apellis Announces Late-Breaking Presentation Of Largest Retrospective Database Study In Geographic Atrophy At AAO 2020 Virtual Benzinga

10:40AM EST Apellis Announces Late-Breaking Presentation of Largest GlobeNewswire Inc

07:19AM EST Appili Therapeutics Reports EPS OF C$($0.09) For Six Months Ended Sept. 30 Benzinga

Nov 11, 2020

07:00AM EST Apellis Pharmaceuticals,Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will participate in the upcoming investor conferences in November: GlobeNewswire Inc

Nov 5, 2020

07:00AM EST -- Eight abstracts accepted for presentation emphasize the potential of targeted C3 therapy to elevate the standard of care in paroxysmal nocturnal hemoglobinuria (PNH) GlobeNewswire Inc

Nov 2, 2020

07:17AM EST Apellis Pharmaceuticals Q3 EPS $(1.79) Down From $(1.09) YoY, Sales $646.00K Benzinga

07:17AM EST Apellis Pharmaceuticals Q3 EPS $(1.79) Down From $(1.09) YoY Benzinga

07:00AM EST Apellis Pharmaceuticals Reports Third Quarter 2020 Financial Results GlobeNewswire Inc

Oct 27, 2020

07:36AM EDT Apellis And Sobi Enter Collaboration For Global Co-development And Ex-US Commercialization Of Systemic Pegcetacoplan In Rare Diseases With Urgent Need For New Treatments; Sobi Will Make An Upfront Payment Of $250M To Apellis, Up To $915M In Milestones Benzinga

07:00AM EDT Apellis and Sobi Enter Collaboration for Global Co-development and GlobeNewswire Inc

Oct 19, 2020

07:04AM EDT Apellis Announces 18-Month Data from Phase 1b Study of Pegcetacoplan in Patients with Geographic Atrophy Benzinga

07:00AM EDT Apellis Announces 18-Month Data from Phase 1b Study of GlobeNewswire Inc

Oct 15, 2020

07:03AM EDT Apellis Announces New Data Demonstrating Correlation between Complement Activation and COVID-19 Severity Benzinga

07:00AM EDT -- Observational study in 41patients hospitalized with COVID-19found that nearly all patients had elevated systemic levels of C3a, a marker forC3 activation; median C3a levelswere 3.7 times the upper limit of normal GlobeNewswire Inc

Oct 9, 2020

10:15AM EDT Apellis to Present Positive Results from the Phase 2 DISCOVERY Study of Pegcetacoplan in C3 Glomerulopathy at ASN Kidney Week Benzinga

10:15AM EDT -- Results demonstrate a greater than 65% mean reduction in proteinuria at week 48 in C3G patients treated with pegcetacoplan -- Sustained improvements were seenacross key clinicalmeasures at 48 weeks -- There are no approved medicines for C3G, a rare disease that often leads to kidney failure GlobeNewswire Inc

Oct 7, 2020

04:05PM EDT Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq GlobeNewswire Inc

Oct 5, 2020

07:12AM EDT Apellis Initiates Registrational Programs Of Pegcetacoplan In Patients With C3G / IC-MPGN And ALS, Rare Diseases With High Unmet Need Benzinga

07:00AM EDT -- Advancing Phase 2 and Phase 3 studiesof the companys targeted C3 therapy inC3G / IC-MPGN, rare kidney diseases with no approved medicines. First patient in Phase 2 study expected to be dosed by the end of the year -- Potentially registrational Phase 2 study in ALS to enroll ~200 adults globally. First patient expected to be dosed by the end of the year GlobeNewswire Inc

Oct 3, 2020

12:50PM EDT Apellis Pharma Presents Results Of Post Hoc Analysis Of Phase 2 FILLY Study Of Intravitreal Pegcetacoplan (APL-2) RTTNews

11:05AM EDT Apellis Announces New Analysis Demonstrating Targeted C3 Therapy GlobeNewswire Inc

Sep 24, 2020

04:05PM EDT Apellis Pharmaceuticals,Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in targeted C3 therapies, today announced that the company will present at Stifels 2020 Immunology and Inflammation Virtual Summit on Thursday, October 1, 2020 at 9:00 a.m. ET. GlobeNewswire Inc

Sep 21, 2020

04:06PM EDT Apellis Announces Late-Breaking Presentation of Targeted C3 Therapy Pegcetacoplan In Patients With Geographic Atrophy At EURETINA 2020 Benzinga

04:05PM EDT -- New analysis of age-related macular degeneration (AMD) progression in Phase 2 FILLY study accepted as late-breaking oral presentation at European Society of Retina Specialists Congress (EURETINA) -- Pegcetacoplan targets C3, and has the potentialto control the irreversible lesion growth in GA, an advanced form of AMD and leading cause of blindness GlobeNewswire Inc

Sep 15, 2020

07:29AM EDT Apellis Announces Submission Of NDA To FDA And EMA For Pegcetacoplan Marketing Applications For Patients With PNH RTTNews

07:02AM EDT Apellis Announces Submission of Pegcetacoplan Marketing Applications to FDA and EMA for Patients with PNH Benzinga

07:00AM EDT Apellis Announces Submission of Pegcetacoplan Marketing GlobeNewswire Inc

Sep 4, 2020

04:06PM EDT Apellis Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635 Benzinga

04:05PM EDT Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq GlobeNewswire Inc

Sep 2, 2020

07:00AM EDT Apellis Pharmaceuticals,Inc. (Nasdaq: APLS) a global biopharmaceutical company pioneering targeted C3 therapies, today announced that the company will participate in the following upcoming investor conferences in September: GlobeNewswire Inc

Sep 1, 2020

09:47AM EDT Benzinga's Top Upgrades, Downgrades For September 1, 2020 Benzinga

05:07AM EDT Stifel Initiates Coverage On Apellis Pharmaceuticals with Buy Rating, Announces Price Target of $40 Benzinga

Aug 21, 2020

04:05PM EDT Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq GlobeNewswire Inc

Jul 31, 2020

07:19AM EDT Apellis Pharmaceuticals Q2 EPS $1.57 Up From $(1.12) YoY Benzinga

07:00AM EDT -- New Drug Application (NDA) and Marketing Authorization Application (MAA) Submissions for Pegcetacoplan in Paroxysmal Nocturnal Hemoglobinuria (PNH) Planned for the Second Half of 2020 GlobeNewswire Inc

Jul 20, 2020

09:16AM EDT Roth Capital Initiates Coverage On Apellis Pharmaceuticals with Buy Rating, Announces Price Target of $50 Benzinga